P196 Healthcare utilisation by patients with Idiopathic Pulmonary Fibrosis; observations from the UK pirfenidone Named Patient Programme

Abstract

Background Methotrexate (MTX) immunosuppressive therapy is selectively used to assist with the reduction of the oral corticosteroid demand thereby decreasing the risk of potential side effects in individuals with steroid dependant asthma. Previous reported data has demonstrated similar significant reduction in corticosteroid load, asthma exacerbation and hospital admission rate. This study aims to compare similar variables collated from UK severe asthma specialist centres to further generate evidence for the continued use of MTX as an effective aid in the reduction of corticosteroid burden in a severe asthma cohort. Methods A retrospective data collection was performed across two UK severe asthma centres with data from a third pending. Patients included had a confirmed diagnosis of severe asthma and had been treated with MTX for at least 12 months to allow sufficient analysis. Variables assessed included mean average daily corticosteroid dose, overall percentage reduction of corticosteroid, exacerbation frequency and acute admission events both twelve months prior to and post commencement of MTX therapy. Data collection was examined for each individual centre then combined and examined for consistency of results. Background It has been suggested that aerosol inhaler characteristics such as fine particle size distribution, low plume velocity, and long duration of the aerosol cloud may assist coordination of inhalation with actuation, improve lung deposition, and reduce oropharyngeal deposition. This study compared 2 ICS/ LABA combination HFA pMDI inhalers: fluticasone propionate/ formoterol 125/5 µg (FP/FORM; flutiform ® ) and fluticasone propionate/salmeterol 125/50 µg (FP/SAL; Seretide ® Evohaler ® ). P195 PLUME CHARACTERISTICS OF FLUTICASONE PROPIONATE/FORMOTEROL PMDI COMPARED WITH FLUTICASONE PROPIONATE/SALMETEROL PMDIMethods Inhalers were operated according to their respective patient information leaflets, and were fired into still air. Plume data were recorded using an Oxford Lasers EnVision Pharma system with high speed CMOS camera and short-pulse laser light source. VidPIV 4.6 & EnVision 1.1.5 software was used to analyse the data and assess velocity and other characteristics of the plume at set intervals from the actuator (up to 9.5 cm which is representative of the distance from mouth to throat). Results FP/FORM pMDI had slower maximum velocity of plume than did FP/SAL at the distances measured (table)

The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review

“…The majority of the studies [ 14 ] reported costs alongside resource use. Four studies reported only HCRU data [ 47 , 90 , 92 , 93 ].…”